These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 37014872

  • 41. Hearing Loss After the First Low Dose Administration of Cisplatin.
    Yildirim A, Fidan E, Ozdemir F.
    J Coll Physicians Surg Pak; 2022 Sep; 32(9):1216-1218. PubMed ID: 36089725
    [Abstract] [Full Text] [Related]

  • 42. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
    Freilich RJ, Kraus DH, Budnick AS, Bayer LA, Finlay JL.
    Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
    [Abstract] [Full Text] [Related]

  • 43. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.
    Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J.
    Pediatr Blood Cancer; 2012 Jul 15; 59(1):144-8. PubMed ID: 22431292
    [Abstract] [Full Text] [Related]

  • 44. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.
    Stöhr W, Langer T, Kremers A, Bielack S, Lamprecht-Dinnesen A, Frey E, Beck JD, German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology.
    Cancer Invest; 2005 Jul 15; 23(3):201-7. PubMed ID: 15945505
    [Abstract] [Full Text] [Related]

  • 45. Molecular Characteristics of Cisplatin-Induced Ototoxicity and Therapeutic Interventions.
    Tan WJT, Vlajkovic SM.
    Int J Mol Sci; 2023 Nov 20; 24(22):. PubMed ID: 38003734
    [Abstract] [Full Text] [Related]

  • 46. Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy.
    Niemensivu R, Saarilahti K, Ylikoski J, Aarnisalo A, Mäkitie AA.
    Eur Arch Otorhinolaryngol; 2016 Sep 20; 273(9):2509-14. PubMed ID: 26685859
    [Abstract] [Full Text] [Related]

  • 47. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration.
    Waters GS, Ahmad M, Katsarkas A, Stanimir G, McKay J.
    Ear Hear; 1991 Apr 20; 12(2):91-102. PubMed ID: 2065844
    [Abstract] [Full Text] [Related]

  • 48. Age-corrected hearing loss after chemoradiation in cervical cancer patients.
    Marnitz S, Schermeyer L, Dommerich S, Köhler C, Olze H, Budach V, Martus P.
    Strahlenther Onkol; 2018 Nov 20; 194(11):1039-1048. PubMed ID: 30120496
    [Abstract] [Full Text] [Related]

  • 49. Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy.
    Driessen CML, Leijendeckers J, Snik A, van der Graaf WTA, de Boer JP, Gelderblom H, Kaanders JHAM, Takes R, van Herpen CML.
    Head Neck; 2019 Feb 20; 41(2):488-494. PubMed ID: 30536479
    [Abstract] [Full Text] [Related]

  • 50. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
    Ekborn A, Hansson J, Ehrsson H, Eksborg S, Wallin I, Wagenius G, Laurell G.
    Laryngoscope; 2004 Sep 20; 114(9):1660-7. PubMed ID: 15475801
    [Abstract] [Full Text] [Related]

  • 51. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
    Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Rasch CR, Schornagel JH, Dreschler WA, Balm AJ.
    Int J Radiat Oncol Biol Phys; 2007 Aug 01; 68(5):1320-5. PubMed ID: 17418969
    [Abstract] [Full Text] [Related]

  • 52. Hearing Loss Risk in Pediatric Patients Treated with Cranial Irradiation and Cisplatin-Based Chemotherapy.
    Cohen-Cutler S, Wong K, Mena V, Sianto K, Wright MA, Olch A, Orgel E.
    Int J Radiat Oncol Biol Phys; 2021 Aug 01; 110(5):1488-1495. PubMed ID: 33677052
    [Abstract] [Full Text] [Related]

  • 53. Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing : Retrospective analysis of 29 medulloblastoma patients.
    Scobioala S, Parfitt R, Matulat P, Kittel C, Ebrahimi F, Wolters H, Am Zehnhoff-Dinnesen A, Eich HT.
    Strahlenther Onkol; 2017 Nov 01; 193(11):910-920. PubMed ID: 28887665
    [Abstract] [Full Text] [Related]

  • 54. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL, Simis YJ, Lansdaal PE, Rasch CR, Tange RA, Balm AJ, Dreschler WA.
    Audiol Neurootol; 2006 Nov 01; 11(5):318-30. PubMed ID: 16983183
    [Abstract] [Full Text] [Related]

  • 55. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
    Bass JK, Huang J, Onar-Thomas A, Chang KW, Bhagat SP, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Heath JA, McCowage G, Cohn RJ, Fisher MJ, Robinson G, Broniscer A, Gajjar A, Gurney JG.
    Pediatr Blood Cancer; 2014 Apr 01; 61(4):601-5. PubMed ID: 24504791
    [Abstract] [Full Text] [Related]

  • 56. Audiological follow-up in transplant patients treated with calcineurin immunosuppressants "Calcineurin inhibitors and Ototoxicity".
    Heider C, Waissbluth S, Oyarzún J, Calderara G, Leung JS, Novoa I.
    Rev Med Chil; 2023 Jun 01; 151(6):702-710. PubMed ID: 38801378
    [Abstract] [Full Text] [Related]

  • 57. Combined genetic polymorphisms of the GSTT1 and NRF2 genes increase susceptibility to cisplatin-induced ototoxicity: A preliminary study.
    Fujikawa T, Ito T, Okada R, Sawada M, Mohri K, Tateishi Y, Takahashi R, Asakage T, Tsutsumi T.
    Hear Res; 2024 Apr 01; 445():108995. PubMed ID: 38518393
    [Abstract] [Full Text] [Related]

  • 58. Asymmetric sensorineural hearing loss is a risk factor for late-onset hearing loss in pediatric cancer survivors following cisplatin treatment.
    Robertson MS, Hayashi SS, Camet ML, Trinkaus K, Henry J, Hayashi RJ.
    Pediatr Blood Cancer; 2019 Jan 01; 66(1):e27494. PubMed ID: 30334605
    [Abstract] [Full Text] [Related]

  • 59. Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.
    Spracklen TF, Vorster AA, Ramma L, Dalvie S, Ramesar RS.
    Pharmacogenomics J; 2017 Dec 01; 17(6):515-520. PubMed ID: 27457817
    [Abstract] [Full Text] [Related]

  • 60. [Ototoxicity of cisplatin in children with malignant diseases].
    Hadjilaskari P, Fengler R, Hartmann R, Henze G.
    Klin Padiatr; 1989 Dec 01; 201(4):316-21. PubMed ID: 2779137
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.